Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk of mortality and heart failure (HF) hospitalization. We examined the frequency and significance of episodes of outpatient HF worsening,...

Descripción completa

Detalles Bibliográficos
Autores principales: Docherty, Kieran F., Jhund, Pardeep S., Anand, Inder, Bengtsson, Olof, Böhm, Michael, de Boer, Rudolf A., DeMets, David L., Desai, Akshay S., Drozdz, Jaroslaw, Howlett, Jonathan, Inzucchi, Silvio E., Johanson, Per, Katova, Tzvetana, Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe A., Merkely, Béla, Nicolau, Jose C., O’Meara, Eileen, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Tereshchenko, Sergey, Verma, Subodh, McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580857/
https://www.ncbi.nlm.nih.gov/pubmed/32883108
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580857/
https://www.ncbi.nlm.nih.gov/pubmed/32883108
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047480

Ejemplares similares